Overview

A Trial to Compare Efficacy and Safety of Follitropin Delta Versus Placebo (Inactive Treatment) in the Treatment of Men With Idiopathic Infertility (Unexplained Reduction of Semen Quality) (ADAM)

Status:
Not yet recruiting

Trial end date:
2024-12-24

Target enrollment:

Participant gender:

Summary

The primary purpose of this trial is to investigate whether men with idiopathic infertility (unexplained reduction of semen quality), after being treated with a daily dose of 12 µg recombinant follicle stimulating hormone (rFSH) for 6 months, can improve the chance of spontaneous pregnancy observed in their female partners in comparison to placebo (inactive treatment).

Phase:

Phase 2

Details

Lead Sponsor:

Ferring Pharmaceuticals

Treatments:

Follicle Stimulating Hormone